FindTrial
Sign In

Cardiovascular Disease (CVD) Risk Assessment and Lipid Lowering Treatment in Type 2 Diabetes Mellitus Patients Treated at Secondary and/or Tertiary Hospitals in Korea

Cardiovascular Disease (CVD) Risk Assessment and Lipid Lowering Treatment in Type 2 Diabetes Mellitus Patients Treated at Secondary and/or Tertiary Hospitals in Korea

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0004984
Enrollment
2000
Registered
2020-05-06
Start date
2020-05-04
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Pfizer Upjohn Korea
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adult Type 2 diabetes mellitus patients (=20 years) treated at secondary and/or tertiary hospitals 2. Patients with a record on cholesterol level at the time of enrollment

Exclusion criteria

Exclusion criteria: 1. Patients currently participating in other drug-controlled interventional study 2. Patients in severe or unstable medical conditions by physicians’ discretion during the recruitment

Design outcomes

Primary

MeasureTime frame
the risks of cardiovascular diseases;lipid lowering treatments;the concordance with clinical practice guidelines—

Secondary

MeasureTime frame
the lipid lowering treatment modifications—

Countries

Korea, Republic of

Contacts

Public ContactSung-Rae Kim

The Catholic University of Korea, Bucheon St. Mary's Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026